Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases. Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumes REYKJAVIK, Iceland, Dec. 23, 2024...
Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first...
REYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
REYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
REYKJAVIK, Iceland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients...
REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously...
REYKJAVIK, Iceland, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio®Sales of Entyvio (vedolizumab) were about $5.4...
REYKJAVIK, Iceland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.5 | 4.00320256205 | 12.49 | 13 | 12.3 | 73940 | 12.58870773 | CS |
| 4 | 1.25 | 10.6473594549 | 11.74 | 13 | 11.26 | 153805 | 11.89136997 | CS |
| 12 | 0.72 | 5.86797066015 | 12.27 | 13.3 | 9.15 | 115001 | 12.30750432 | CS |
| 26 | 0.69 | 5.60975609756 | 12.3 | 13.3 | 9.15 | 106585 | 12.05860578 | CS |
| 52 | 1.5 | 13.0548302872 | 11.49 | 18 | 9.15 | 175475 | 13.77777633 | CS |
| 156 | 3.49 | 36.7368421053 | 9.5 | 18 | 5.2 | 115804 | 12.15813039 | CS |
| 260 | 3.49 | 36.7368421053 | 9.5 | 18 | 5.2 | 115804 | 12.15813039 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
